Jeevan Scientific Technology Limited’s Post

✨ 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 𝗮𝗻𝗱 𝗙𝗶𝗯𝗿𝗼𝗚𝗲𝗻 𝗦𝗲𝗰𝘂𝗿𝗲 𝗨.𝗦. 𝗥𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝗥𝗼𝘅𝗮𝗱𝘂𝘀𝘁𝗮𝘁 𝗔𝗺𝗶𝗱 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀! 🌐 𝗜𝗻 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟰, The U.S. rights to the HIF-PH inhibitor #roxadustat, an oral anemia medication, were granted to AstraZeneca and FibroGen, Inc.The news was made about ten months after roxadustat was shown to be ineffective in a phase 3 trial involving #anemia patients who had #myelodysplastic syndromes (MDS), a class of #blood 🩸 cell diseases. Although FibroGen is still holding onto hope for some purposes, the FDA rejected roxadustat in 2021 for use in anemia related to chronic renal disease, which looked to put an end to the #drugs journey to the U.S. market due to the trial's failure. The FDA required a new trial design for any future refiling, but FibroGen and AZ were unable to come to an agreement on it once roxadustat received the expected comprehensive response letter.  𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗟𝗶𝗻𝗸𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/3P1uWiO #fdaapproval  #sicklecellanemia #clinicaltrials  #healthcare #prophecymarketinsights

The significance of Regulatory CMC is magnified in the context of Orphan Drug Status due to the urgent need for therapies in rare disease populations. These patients frequently have limited or no treatment options, underscoring the necessity for rapid development and approval of new drugs. The FDA's focused efforts to address this need are evident, with over half of the Center for Drug Evaluation and Research's (CDER) novel drug approvals in 2023 targeting rare diseases. This emphasis highlights the critical role of Regulatory CMC in ensuring the quality, safety, and efficacy of these urgently needed treatments but also underscores the importance of streamlined and efficient regulatory pathways to bring these therapies to patients swiftly. The detailed outcomes and impact of these approvals on rare disease treatment landscapes can be further explored in the specified sections of the recent FDA report, providing valuable insights into the advancements in this vital area of drug development. FDA Enkrisi #FDA #CMC

In 2023, the FDA's Center for Drug Evaluation and Research (CDER) played a pivotal role in bringing groundbreaking drug therapies to patients and consumers. From the approval of the first oral antiviral pill for COVID-19 to advancements in combating opioid overdose, CDER's efforts are transforming patient care. But that's not all! CDER's 2023 approvals cover a wide range of diseases and conditions, offering hope to patients with rare diseases and enhancing treatment options across the board. Curious to learn more about CDER's impactful work? Click the link to read the full information. #HealthcareInnovation #FDAApprovals #Raredisease #PatientCare #InviMedsHealth #ReadMore

Curious about Konzo? This preventable disease can have serious consequences. Want to learn more about its causes, symptoms, and prevention strategies? DM us "konzo" for exclusive information and tips. Let's work together to combat this health issue. Visit: www.ppg.edu.in #medicalcollegeincoimbatore #PPGcollege #pharmaceuticals #medicaleducation #konzo #konzoawarness #symptoms #symptomsofkonzo #ppgcollegeofpharmacy #pharmacy #pharmacist #healthandwellness #HealthCare #health #trendingvideo #shortsvideos #shortsviral #NeurologicalCondition #n#neurologicaldisorder #NeurologicalCare

Respiratory and nasal challenge tests in a clinical trial can expedite drug development by demonstrating target engagement and efficacy prior to patient exposure in a relatively small study in a well-controlled environment. In addition, bioavailability assessment during a nasal allergen assessment is essential for drugs intranasally administered. Learn about the merits and limitations of various respiratory and nasal challenge tests: https://lnkd.in/eXNC4pAC https://lnkd.in/gGJbzGP #RespiratoryChallenge #AllergenChallenge #RespiratoryCenterOfExcellence #BelfastClinic

This Vascular Disease Awareness Month we are talking about high blood pressure, also known as hypertension. 📈 According to a recent study, the number of people affected by high blood pressure has almost doubled over the past 40 years, with about 1.13 billion people living with the condition worldwide. Did you know that there are different types of hypertension? Find out more below... ⬇️ #VascularDiseaseAwarenessMonth #Healthcare #Pharmaceuticals

April is Parkinson’s Awareness Month, so I wanted to take a moment to reflect on the impact of this disease. According to the Parkinson's Foundation, nearly one million Americans are living with Parkinson’s disease, a number expected to rise to 1.2 million by 2030. This statistic underscores the urgency and relevance of treatments and access to medications. At PAI, we are proud to contribute to the care of those affected as we manufacture and distribute amantadine oral solution, an anti-Parkinson medication. This formulation is especially significant for patients who experience difficulties with swallowing—a common challenge among the pediatric and geriatric populations. Access to an FDA approved amantadine oral solution ensures that these vulnerable groups are not left behind in efforts to manage Parkinson’s symptoms effectively. In the pharmaceutical industry, it’s crucial to remember the human element in everything we do. Our commitment at PAI Pharma goes beyond manufacturing medications; it’s about making a positive, tangible impact in the lives of patients and their families. By highlighting some of the treatments we provide, I hope to help ensure that every patient feels seen, heard, and cared for, and ensure our employees connect to the impact they’re making. #ParkinsonsAwareness #pharmaceuticals

This narrative review examines the current evidence of pre-emptive pharmacogenetic/omic (PGx) testing-based treatment for the prevention of adverse drug reactions (ADRs) incidence and hospitalization or emergency department visits due to serious ADRs, thus improving patient safety.   Published in The Pharmacogenomic Journal. Read via Springer Nature Group.   ➡ https://lnkd.in/gX8bUN8u | #Pharmacogenetics #Pharmacogenomics #PGx #AdverseDrugReactions #ADRs #PtSafety

🚨 FDA Approves VOQUEZNA® (vonoprazan) for Erosive Esophagitis! 💊 VOQUEZNA® (vonoprazan) is now approved for treating erosive esophagitis and related heartburn in adults. 🔬 Vonoprazan has shown superior efficacy in clinical trials compared to lansoprazole, particularly in healing severe esophagitis. 💡Available in 10 mg and 20 mg doses, with common side effects including gastritis, nausea, and abdominal pain. 📝 Long-term use may lead to conditions like hypertension and urinary tract infections. 📄 Read more about this new treatment option: https://lnkd.in/ddgFAu8T 👉 P.S. Stay informed about the latest developments in pharmaceuticals and healthcare! 👨⚕️ Follow me Muhammad Mannan Ashfaq and press the bell icon on my profile to get latest updates. #voquezna #vonoprazan #mannan #erosiveesophagitis #heartburn #gastrohealth #mp4uacademy #fdaapproved #gerdtreatment